Novogene Co

Novogene Co EBITDA Margin

The EBITDA Margin of Novogene Co (688315.SS) as of Oct 27, 2026 is 8.76 %. In the previous year, EBITDA Margin was 12.11 % — a change of -27.65% (lower).

EBITDA Margin

8.76 %

YoY

-27.65%

Last updated:

EBITDA Margin of Novogene Co is 2025 8.76 % . EBITDA Margin of Novogene Co was 2024 12.11 % . It decreases by -27.65% lower compared to the previous year.

The Novogene Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
12.55 CNY
Jan 1, 2019
8.90 CNY
Jan 1, 2020
3.60 CNY
Jan 1, 2021
14.54 CNY
Jan 1, 2022
12.43 CNY
Jan 1, 2023
11.93 CNY
Jan 1, 2024
12.11 CNY
Jan 1, 2025
8.76 CNY
The Novogene Co EBITDA Margin history
YEAREBITDA MarginYoY
8.76 %-27.65%
12.11 %+1.47%
11.93 %-4.02%
12.43 %-14.52%
14.54 %+303.70%
3.60 %-59.52%
8.90 %-29.08%
12.55 %+4.37%
12.02 %+24.34%
9.67 %-1.60%
9.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novogene Co Stock analysis

What does Novogene Co do? Novogene Co., Ltd. generates revenue through genomic services and solutions, primarily utilizing high-throughput sequencing and bioinformatics analysis technologies. The company offers life science basic research services, medical research and technical services, and database-building sequencing platform services, targeting both domestic and international markets. Key products include gene mutation detection kits, coronavirus disease nucleic acid test services, and DA8600 sequencers, which are sold to research institutions, medical facilities, and clinical applications. The firm's technology-driven approach enables it to provide multi-level scientific and research technical services across life science and medical fields. Novogene's revenue streams are anchored in its sequencing platforms and equipment, with the DA8600 sequencers representing a significant product line. The company develops and sells genetic testing medical equipment, leveraging its expertise in gene sequencing. Its services are tailored for life science basic research, medical and clinical applications, and database construction, serving a diverse clientele including research organizations and healthcare providers. The firm's focus on multi-omics research technology enhances its ability to deliver comprehensive solutions. The business model integrates high-throughput sequencing technology with bioinformatics analysis to create scalable services. Novogene's offerings span from basic research support to clinical diagnostic tools, with gene mutation detection kits and coronavirus disease nucleic acid test services catering to specific market needs. The company's domestic and overseas market presence ensures broad client reach, while its independent development of sequencing equipment like the DA8600 sequencers drives product-based revenue. This dual focus on services and equipment positions Novogene as a key player in genomic technology solutions. Novogene Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novogene Co stock

EBITDA Margin of Novogene Co is 8.76 % in 2025.

EBITDA Margin of Novogene Co changed from 12.11 % to 8.76 %, representing a -27.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Novogene Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Novogene Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Novogene Co

All Key Metrics — Novogene Co